Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1655-1662

  Merson, S ^a   Yang, Z H ^b   Brewer, D ^a,c   Olmos, D ^d   Eichholz, A ^a   McCarthy, F ^a   Fisher, G ^b   Kovacs, G ^e   Berney, D M ^b   Foster, C S ^f,g   Moller H ^b,h   Scardino, P ⁱ   Cuzick, J ^b   Cooper, C S ^c   Clark, J P ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g HCA Healthcare Laboratories   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

androgen receptor gene amplification; FISH; hormone na ve; prostate cancer prognosis

Indexed keywords

ANDROGEN RECEPTOR; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENETIC SCREENING; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; PRIORITY JOURNAL; TISSUE MICROARRAY; X CHROMOSOME;

AGED; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SURVIVAL ANALYSIS;

EID: 84896495745     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.13     Document Type: Article

References (30)

1. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS. TransAtlantic Prostate Group (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27: 253-263.
2. Berney DM (2011) The tumour-node-metastasis staging of prostate cancer in transurethral resection of the prostate chips requires revision. BJU Int 107: 351-352.
3. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J (2009) Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100: 888-893.
4. Bonkhoff H, Berges R (2010) From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70: 100-112.
5. Brown RSD, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JMS, Masters JRW (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 198: 237-244.
6. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806.
7. Byar DP (1972) Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol 108: 908-913.
8. Clark J, Attard G, Jhavar S, Flohr P, Reid A, de Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS (2008) Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27: 1993-2003.
9. Cottu PH, Asselah J, Lae M, Pierga J-Y, Diéras V, Mignot L, Sigal-Zafrani B, Vincent-Salomon A (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19: 595-597.
10. Cox D, Oakes D (1984) Analysis of Survival Data. Chapman & Hall: London 201.
11. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P. Transatlantic Prostate Group (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194.
12. De Bono JS, Ashworth A (2010) Translating cancer research into targeted therapeutics. Nature 467: 543-549.
13. Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89: 552-556.
14. Haapala K, Kuukasjärvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA (2007) Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38: 474-478.
15. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319.
16. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
17. Melchior S, Hadaschik B, Thüroff S, Thomas C, Gillitzer R, Thüroff J (2009) Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 103: 1478-1481.
18. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T (1997) Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 31: 216-219.
19. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
20. Reid AHM, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, De Bono JS, Cooper CS. Transatlantic Prostate Group (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102: 678-684.
21. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TLJ. the FinnProstate Group (2013) Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects. Eur Urol 63: 111-120.
22. Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
23. Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-829.
24. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398.
25. Taplin M-E, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B Study 9663 (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21: 2673-2678.
26. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
27. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
28. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149.
29. Waltering KK, Urbanucci A, Visakorpi T (2012) Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 360: 38-43.
30. Warburton PE, Greig GM, Haaf T, Willard HF (1991) PCR amplification of chromosome-specific alpha satellite DNA: definition of centromeric STS markers and polymorphic analysis. Genomics 11: 324-333.